Cargando…
Biphasic human insulin 30 thrice daily, is it reasonable?
OBJECTIVE: To evaluate the efficacy and safety of thrice daily Biphasic Human Insulin 30 (BHI 30) versus the traditional twice-daily regimen in type 2 diabetes mellitus (T2DM) patients. It’s a cross over single clinical study. Twenty-two diabetic patients who were already using BHI 30 in twice or th...
Autores principales: | Saadeh, Nesreen A., Al-Azzeh, Ola Y., Khader, Yousef S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247174/ https://www.ncbi.nlm.nih.gov/pubmed/32448382 http://dx.doi.org/10.1186/s13104-020-05090-6 |
Ejemplares similares
-
Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus – A pilot study
por: Shanmugasundar, G., et al.
Publicado: (2012) -
Comparison of thrice‐daily lispro 50/50 vs thrice‐daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetes
por: Yamashiro, Keiko, et al.
Publicado: (2010) -
28‐week, randomized, multicenter, open‐label, parallel‐group phase III trial to investigate the efficacy and safety of biphasic insulin aspart 70 thrice‐daily injections vs twice‐daily injections of biphasic insulin aspart 30 in patients with type 2 diabetes
por: Kadowaki, Takashi, et al.
Publicado: (2010) -
Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy
por: Heise, Tim, et al.
Publicado: (2009) -
Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving biphasic insulin aspart 30 or biphasic human insulin 30
por: Ohta, Akio, et al.
Publicado: (2011)